Johnson & Johnson's medical device businesses grew 5.3% on an organic basis in the third quarter, led by the Biosense Webster electrophysiology business. The company is increasing R&D investment, especially in robotic surgery, to boost its surgery and orthopedics businesses.
Johnson & Johnson’s medical device business recorded its best quarterly growth since 2015 in the third quarter of 2019, the company reported on 15 October.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.
Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.
OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.
Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.
Abbott has also added new customization options to enhance user comfort and discretion. These include a “silent mode” feature for FreeStyle Libre 3 systems, allowing users to mute glucose alarms for up to six hours – a useful option during meetings, sleep, or other moments where audio alerts may be disruptive.
Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.
Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.
